12:00 AM
Dec 03, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

MyeloXen: Phase I/IIa started

Xenetic said Pharmsynthez began a 3-part, open-label, Russian Phase I/IIa trial of MyeloXen in 26 subjects. The first part will enroll 6 healthy volunteers, while the second and third parts will...

Read the full 135 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >